About Quadrant Biosciences
Quadrant Biosciences is a private company based in Syracuse, New York. It has reported $11,932,450 raised in six offerings on Form D since August 2015.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Not yet | Nov 2, 2023 | $0of $25.4M target | 0 | — | Debt, OptionsRule 506(c) | Form D ↗ |
| Jul 27, 2023 | Aug 8, 2023 | $3,500,000of $35.0M target | 6 | $583K | Debt, OptionsRule 506(b) | Form D ↗ |
| Dec 3, 2019 | Jan 23, 2020 | $2,300,000of $5.0M target | 20 | $115K | EquityRule 506(b) | Form D ↗ |
| Jun 12, 2019 | Jun 27, 2019 | $450,000of $5.0M target | 6 | $75,000 | EquityRule 506(b) | Form D ↗ |
| Nov 30, 2016 | Dec 13, 2016 | $2,080,000of $2.5M target | 30 | $69,333 | EquityRule 506(b) | Form D ↗ |
| Aug 6, 2015 | Aug 19, 2015amended Apr 14, 2016 | $3,602,450of $5.0M target | 36 | $100K | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Total, six offerings | $11,932,450 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Quadrant Biosciences's Form D filed Nov 2, 2023.
Earlier filings also listed Wade West (executive officer and director, last listed Jan 2020), Scott Giambalvo (executive officer, last listed Jan 2020), Randy Carpenter (executive officer, last listed Jan 2020), Patrick Bailey (executive officer, last listed Jan 2020), Kayla Wagner (executive officer, last listed Jan 2020), Jeremy Williams (executive officer, last listed Jan 2020), Chris Horacek (executive officer, last listed Jan 2020) and Benjamin Perry (executive officer, last listed Jan 2020).